Eupraxia Pharmaceuticals Inc. (EPRX)
- Previous Close
2.9300 - Open
2.8200 - Bid 2.7300 x 2000
- Ask 2.8200 x 100
- Day's Range
2.8100 - 2.9000 - 52 Week Range
2.4800 - 3.5000 - Volume
10,618 - Avg. Volume
37,225 - Market Cap (intraday)
100.1M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
www.eupraxiapharma.comRecent News: EPRX
Performance Overview: EPRX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EPRX
Valuation Measures
Market Cap
101.48M
Enterprise Value
75.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
-246.24%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-30.37M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
35.91M
Total Debt/Equity (mrq)
52.78%
Levered Free Cash Flow (ttm)
--